Skip to main content Accessibility help
Hostname: page-component-544b6db54f-fg2fv Total loading time: 0.634 Render date: 2021-10-15T23:43:05.548Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Longitudinal studies of cognition in schizophrenia: Meta-analysis

Published online by Cambridge University Press:  02 January 2018

Andrei Szöke*
INSERM U841, 94000, Créteil, France, Université Paris 12, Faculté de Médecine, IFR 10, 94000, Créteil, France, and AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Anca Trandafir
INSERM U841, 94000, Créteil, France, Université Paris 12, Faculté de Médecine, IFR 10, 94000, Créteil, France, and AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Marie-Estelle Dupont
AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Alexandre Méary
INSERM U841, 94000, Créteil, France, Université Paris 12, Faculté de Médecine, IFR 10, 94000, Créteil, France, and AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Franck Schürhoff
INSERM U841, 94000, Créteil, France, Université Paris 12, Faculté de Médecine, IFR 10, 94000, Créteil, France, and AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Marion Leboyer
INSERM U841, 94000, Créteil, France, Université Paris 12, Faculté de Médecine, IFR 10, 94000, Créteil, France, and AP-HP, Groupe Hospitalier ‘Chenevier-Mondor’, Pôle de Psychiatrie, 94000, Créteil, France
Dr Andrei Szöke, Service de Psychiatrie Adulte, Hôpital Albert Chenevier, 40 rue de Mesly, 94000 Créteil, France. Email:
Rights & Permissions[Opens in a new window]



A wide range of cognitive deficits have been demonstrated in schizophrenia, but their longitudinal course remains unclear.


To bring together all the available information from longitudinal studies of cognitive performance in people with schizophrenia.


We carried out a meta-analysis of 53 studies. Unlike previous reviewers, we included all studies (regardless of the type of medication), analysed each variable separately and compared results with data from controls.


Participants with schizophrenia showed a significant improvement in most cognitive tasks. The available data for controls showed, with one exception (the Stroop test), a similar or greater improvement. Performance in semantic verbal fluency remained stable in both individuals with schizophrenia and controls.


Participants with schizophrenia displayed improvement in most cognitive tasks, but practice was more likely than cognitive remediation to account for most of the improvements observed. Semantic verbal fluency may be the best candidate cognitive endophenotype.

Review Article
Copyright © Royal College of Psychiatrists, 2008 

People with schizophrenia have been shown to have a wide range of cognitive deficits, but the longitudinal course of these deficits remains unclear. Some studies have suggested that cognitive function deteriorates over time, Reference Goldberg, Weinberger, Berman, Pliskin and Podd1,Reference Bilder, Lipschutz-Broch, Reiter, Geisler, Mayerhoff and Lieberman2 whereas others have reported stability or even an improvement in some functions. Reference DeLisi, Tew, Xie, Hoff, Sakuma, Kushner, Lee, Shedlack, Smith and Grimson3,Reference Rund4 This issue is important for several reasons. First, it could help to resolve the perennial debate between those who conceptualise schizophrenia as a neurodegenerative, progressive disorder and those who view it as a stable deficit stemming from a developmental defect. Second, cognitive deficits have come to be considered as potential endophenotypes that might facilitate the identification of genetic factors involved in vulnerability to schizophrenia. For a measure to be considered a good endophenotype, it must be stable over time or the non-genetic factors influencing it must be identified and used to obtain a standardised (adjusted) value. Finally, there is growing interest in improving cognitive functions in patients with schizophrenia through pharmacological treatment or cognitive rehabilitation programmes, as a means of improving functional outcome. Reference Gold5 We therefore need to identify the cognitive deficits that are not fixed and the tests and variables that are most sensitive to change, to facilitate the monitoring of results.

In this study we analysed the available information by meta-analysis of all studies in which the same sample of people with schizophrenia underwent cognitive testing on two separate occasions more than 1 month apart.


We based our search for relevant articles on three complementary procedures. We first searched the Medline database, limiting our search to: HUMAN, ADULT and PUBLICATION DATE 1978–2006. We identified relevant articles by searching for (SCHIZO* or PSYCHOTIC) and (COGNIT*) and (RETEST or LONGITUDINAL). The second term (COGNIT*) was replaced with a succession of terms describing cognitive domains (MEMORY, EXECUTIVE, ATTENTION) or the names of frequently used cognitive tests (WECHSLER MEMORY SCALE or WMS, WISCONSIN or WCST, TRAIL MAKING TEST or TMT, VERBAL FLUENCY, CONTINUOUS or CPT, STROOP, CALIFORNIA or CVLT, DIGIT SPAN). We also obtained additional references from the two practitioner's guides to evaluating change edited by McCaffrey et al. Reference McCaffrey, Duff and Westervelt6,Reference McCaffrey, Duff and Westervelt7 We then screened the reference lists of these articles to find other studies on the subject. Finally, we manually searched recent issues (from January 2003 to March 2006) of seven major psychiatric journals considered relevant to this study: Schizophrenia Research, Archives of General Psychiatry, American Journal of Psychiatry, British Journal of Psychiatry, Psychiatry Research, Schizophrenia Bulletin and Journal of Nervous and Mental Disease.

Selection of articles for inclusion in the meta-analysis

We selected articles satisfying the following criteria:

  1. (a) diagnosis of schizophrenia in patients (according to Research Diagnostic Criteria, DSM–III, DSM–III–R or DSM–IV, ICD–9 or ICD–10);

  2. (b) participants aged over 18 years;

  3. (c) results reported separately for each task (i.e. not only as composite scores) on both occasions;

  4. (d) sufficient data available to calculate the effect (i.e. mean and standard deviation, F or t statistics) in at least three studies for each cognitive test;

  5. (e) data independent of the other data included in our meta-analysis (if several articles dealt with the same population, we selected only the article with the largest sample);

  6. (f) at least 1 month between test and retest and no specific training to improve performance in the test used (to minimise practice effects).

Recorded variables

From each study we extracted the following variables, if available:

  1. (a) name of the first author and year of publication;

  2. (b) the cognitive tests used;

  3. (c) diagnosis of participants (i.e. only schizophrenia, or schizophrenia and other psychotic disorders);

  4. (d) number of participants included at each evaluation;

  5. (e) time (months) between test and retest;

  6. (f) type of treatment and dosage (in chlorpromazine equivalents) at the time of the first and second evaluations. Type of treatment was recorded as a dichotomous variable: typical antipsychotic drugs (neuroleptics) v. atypical (novel) antipsychotic drugs;

  7. (g) percentage change in positive and negative scores between test and retest, measured using the Scale for the Assessment of Negative Symptoms (SANS), the Scale for the Assessment of Positive Symptoms (SAPS) and the Positive and Negative Syndrome Scale (PANSS);

  8. (h) results of tests (mean; s.d.) from the two evaluations or statistics (F, t) and direction of change if the mean and s.d. were unavailable; if data were provided for more than two evaluations we used only data from the first two, to minimise practice effects.

The variables (c) to (g) were recorded because they were considered potential moderators of the difference between the two measures of cognitive performance.

Meta-analytical procedure

We analysed each measure from each cognitive test separately, without grouping variables from several tests into composite scores for large cognitive domains. We felt that this strategy would be the most effective way to identify longitudinal changes in specific cognitive processes and the most useful variables for genetic research (those providing stable measures) or for assessing treatment impact (those changing over time).

Using the data reported in each study, we estimated the effect size by calculating Hedges' unbiased g, Reference Hedges and Olkin8 with positive values reflecting better performances on retesting (second evaluation) than at first evaluation. We tested the homogeneity of effect sizes using the I Reference Bilder, Lipschutz-Broch, Reiter, Geisler, Mayerhoff and Lieberman2 statistic, as described by Higgins & Thompson. Reference Higgins and Thompson9 As suggested by these authors, values exceeding 30% were considered to indicate significant heterogeneity.

For homogeneous data, we calculated the global effect size, using a fixed effect model as described by Hedges & Olkin. Reference Hedges and Olkin8 In the absence of significant heterogeneity, the use of a fixed effect model is legitimate and may provide greater statistical power than the random effect model. For heterogeneous studies we used the sample-adjusted meta-analytic deviancy (SAMD) and scree plots Reference Arthur, Bennett and Huffcutt10 to identify studies with extreme values (outliers). The SAMD statistic compares the value of each study with the mean sample-weighted value calculated with that study excluded from the analysis, adjusting for the sample size of the study. A study is considered to be an outlier if its SAMD value is greater than 3.0 or if it produces a drastic break in the SAMD scree plot. When these procedures identified clear outliers (small numbers of studies isolated by a drastic break in the scree plot and with SAMD values exceeding 3), the data from these studies were removed and analyses were carried out as previously described. Data for outliers were analysed to identify, when possible, the origin of the heterogeneity. When the SAMD and scree plot procedures failed to identify outliers clearly we used a random effect model Reference DerSimonian and Laird11 to calculate global effect size.

For comparison purposes we used the same analytical procedures to calculate the effects in control samples. A comprehensive evaluation of the differences between test and retest results in healthy controls was beyond the scope of this study. We therefore restricted our analysis to control samples from the studies included in our meta-analysis, together with data from studies cited by McCaffrey et al. Reference McCaffrey, Duff and Westervelt6,Reference McCaffrey, Duff and Westervelt7 For each variable, separate analyses were conducted for samples derived from studies included in our meta-analysis and for all samples (from our meta-analysis and from McCaffrey et al). Reference McCaffrey, Duff and Westervelt6,Reference McCaffrey, Duff and Westervelt7

For the tests for which more than ten samples were available, we assessed the influence of potential moderator variables with a one-factor fixed-effect model. Reference Wang and Bushman12 The potential moderator variables tested were time between the two evaluations; diagnosis of the participants (schizophrenia only, or schizophrenia and other psychotic disorders); change of treatment type v. same type of antipsychotic treatment (typical or atypical); difference in dosage of antipsychotic medication (chlorpromazine equivalents) between test and retest; percentage change in negative symptoms; and percentage change in positive symptoms.


We identified 131 potentially relevant studies, 53 of which met the inclusion criteria. The selection process is illustrated in Fig. 1. The tests used for each study are listed in a data supplement to the online version of this paper. In total, 2476 people with schizophrenia participated in the 53 studies selected. The mean time between test and retest was 12 months (median 4 months) and the mean age of these participants was 37 years. Only 12 of the studies included in our analysis had a healthy control group (total number of control participants 324). We analysed the data for 11 tests (see online data supplement) and 31 variables available from more than three studies.

Fig. 1 Selection process for the articles included in the meta-analysis.

Analysis of effect sizes in the schizophrenia group samples

We analysed each test independently; however, for clarity the results are presented according to the categories of memory, executive function, attention and ‘other tests’.


The selected articles contained data for nine variables, from six tests exploring various aspects of memory. Two of these tests assessed visual memory: the Rey Complex Figure test and Visual Reproduction from the Wechsler Memory Scale (WMS). The remaining four assessed verbal memory: the California Verbal Learning Test (CVLT), Logical Memory from the WMS, the Hopkins Verbal Learning Test (HVLT) and the Rey Auditory Verbal Learning Test (RAVLT). The results are summarised in Table 1.

Table 1 Change between test and retest in variables derived from the memory tests

Test Visual/verbal Recall/recognition Immediate/delayed Studies n Samples n Participants n Estimated effect (95%CI)
Rey Complex Figure Visual Recall Immediate 5 9 161 0.53 (0.31 to 0.76)
WMS Visual Reproduction Visual Recall Delayed 10 14 450 0.30 (0.16 to 0.43)
WMS Visual Reproduction Visual Recall Immediate 11 15 400 0.20 (0.06 to 0.34)
RAVLT a Verbal Recall Immediate 5 11 377 0.31 (0.16 to 0.45)
HVLT Verbal Recognition Immediate 5 10 252 0.33 (0.10 to 0.55) b
HVLT Verbal Recall Delayed 3 6 167 0.33 (–0.05 to 0.70) b
CVLT Verbal Recall Immediate 4 4 159 0.32 (0.10 to 0.54)
WMS Logical Memory Verbal Recall Immediate 10 13 380 0.30 (0.15 to 0.44)
WMS Logical Memory Verbal Recall Delayed 9 12 360 0.30 (0.16 to 0.45)

CVLT, California Verbal Learning Test; HVLT, Hopkins Verbal Learning Test; RAVLT, Rey Auditory Verbal Learning Test; WMS, Wechsler Memory Scale/Wechsler Memory Scale Revised

a. Data from one study excluded (outlier)

b. Calculated using a random effect model

For three variables (RAVLT immediate recall, HVLT immediate recall and HVLT delayed recall), the data were heterogeneous. The SAMD and scree plot analyses failed to identify clear outliers for the two variables from the HVLT. Thus, for these variables the global effect was calculated by a random effect procedure. For the RAVLT, one study Reference Stip, Remington, Dursun, Reiss, Rotstein, MacEwan, Chokka, Jones and Dickson13 was identified as an outlier (SAMD 3.72, and a clear break in the scree plot). Following the exclusion of this study, the other data were homogeneous and the global effect was therefore calculated using a fixed effect model. Stip et al Reference Stip, Remington, Dursun, Reiss, Rotstein, MacEwan, Chokka, Jones and Dickson13 obtained the largest improvement in the RAVLT. They reported results for cognitive assessment at baseline and for the last observation carried forward, which was, for most participants, the third assessment. Other studies used a similar design, Reference Purdon, Jones, Stip, Labelle, Addington, David, Breier and Tollefson14,Reference Purdon, Malla, Labelle and Lit15 but the intervals between assessments were shorter in Stip's study (4 weeks), increasing the effect of practice and potentially accounting for the observed results.

The estimated effects for memory tests ranged from 0.20 for immediate recall in the Visual Reproduction test to 0.53 for immediate recall in the Rey Complex Figure test. Significant improvements were observed in all tests except HVLT delayed recall. The characteristics of the tests (visual or verbal, recall or recognition, immediate or delayed) had no clear influence on the magnitude of improvement at retest (Table 1).

Executive functions

We were able to calculate a global estimate of the difference between test and retest for ten variables from five tests of executive functions (Table 2): (lexical and semantic Verbal Fluency, the Stroop test, the Wisconsin Card Sorting Test (WCST) and the Trail Making Test part B (TMT–B).

Table 2 Change between test and retest in variables derived from the executive tests

Test Variable Studies n Samples n Participants n Estimated effect (95% CI)
Verbal Fluency (Letters) Total words 25 38 1186 0.20 (0.12 to 0.28)
Verbal Fluency (Categories) Total words 7 13 601 0.02 (–0.10 to 0.14)
Stroop Coloured words 8 11 358 0.28 (0.02 to 0.53) a
TMT–B Errors 3 4 71 0.28 (–0.06 to 0.61)
TMT–B Time 27 36 1191 0.23 (0.14 to 0.31)
WCST b Percentage of perseverative errors 8 11 297 0.21 (0.04 to 0.37)
WCST Total number of errors 5 8 287 0.17 (0.01 to 0.34)
WCST Number of perseverative errors 14 23 637 0.16 (0.05 to 0.28)
WCST Number of perseverative responses 5 7 144 0.13 (–0.11 to 0.36)
WCST Number of categories completed 22 29 1013 0.12 (0.03 to 0.21)

TMT–B, Trail Making Test part B; WCST, Wisconsin Card Sorting Test

a. Calculated using a random effect model

b. Data from one study excluded (outlier)

Data were homogeneous for all but two variables: percentage perseverative error in the WCST and number of coloured words in the interference task of the Stroop test. For the percentage of perseverative errors in the WCST, the SAMD identified the study by Penades et al Reference Penades, Boget, Catalan, Bernardo, Gasto and Salamero16 as an outlier (SAMD 3.73, and break in the scree plot). The remaining data were homogeneous once the data from this study had been excluded. Penades et al Reference Penades, Boget, Catalan, Bernardo, Gasto and Salamero16 studied patients who underwent cognitive rehabilitation therapy between test and retest, potentially accounting for the greater improvement between test and retest observed in this study (estimated effect 1.35, 95% CI 0.72–1.98).

The results obtained for the number of coloured words in the interference task of the Stroop test were highly heterogeneous, with the effects in the various studies ranging from −0.32 to 0.99 (P=0.004). The use of different formats of this classic test in the various studies is the most likely explanation for this difference. Indeed, a 60 s format was used in one study, the 90 s format was used in two studies, a 100 s task in another study and two more studies referred to the original article by Stroop published in 1935 – which, however, did not use the number of coloured words as a response variable. Two studies did not describe the format of the Stroop task used. No clear outlier was identified through the SAMD or scree plot procedures, so global effect was calculated using the random effect procedure.

The estimated effects for the executive functions tasks ranged from 0.02 to 0.28, with slight improvements observed for certain tasks, and no significant difference for others.


In the studies included in our analysis, we identified six variables from four tests generally considered to measure attentional processes. The results for these variables are summarised below (Table 3).

Table 3 Change between test and retest in variables derived from the attention tests

Test Variable Studies n Samples n Participants n Estimated effect (95% CI)
Digit Span Number of digits 11 15 330 0.13 (–0.03 to 0.28)
DSDT a Correct responses 5 8 251 0.11 (–0.06 to 0.28)
Stroop Coloured dots 3 4 153 0.15 (–0.08 to 0.37)
Stroop Words 3 4 153 0.13 (–0.10 to 0.35)
TMT–A Time 17 23 840 0.27 (0.18 to 0.37)
TMT–A Errors 3 4 73 0.08 (–0.25 to 0.41)

DSDT, Digit Span Distractibility Task; TMT–A, Trail Making Test part A

a. Data from one study excluded (outlier)

The data for the Digit Span Distractibility Task were heterogeneous. We therefore carried out analyses to identify outliers. The SAMD for the study by Green et al Reference Green, Marshall, Wirshing, Ames, Marder, McGurk, Kern and Mintz17 was 4.07, and this study was therefore excluded from the analysis for this task. Green's study reported the greatest improvement of any of the studies using this test (estimated effect 1.01, 95% CI 0.48–1.56). No potential moderator variable that could account for the heterogeneity of the data was identified.

The estimated effects of attentional tasks ranged from 0.08 to 0.27, with only that for the Trail Making Test part A (time) being significant.

Other tests

Six other tasks that could not be grouped into any meaningful category were analysed (Table 4). Four were from the Wechsler Adult Intelligence Scale (WAIS): two verbal tasks (Similarities and Vocabulary), one task assessing psychomotor performance (Digit Symbol Substitution) and one assessing visuospatial conceptualisation (Block Design). The effects obtained for these tasks were small but (with the exception of Vocabulary) significant, showing a slight improvement between test and retest. The other two tests analysed, the Boston Naming Test and Rey Complex Figure (copy), showed a small, non-significant change between test and retest.

Table 4 Change between test and retest in variables derived from the ‘other’ (not classified) tests

Test Cognitive process Studies n Samples n Participants n Estimated effect (95% CI)
Similarities Verbal concept formation 4 8 152 0.36 (0.13 to 0.59)
Digit Symbol Psychomotor performance, sustained attention 7 11 215 0.28 (0.10 to 0.48)
Block Design Visuospatial conceptualisation 9 14 368 0.22 (0.08 to 0.37)
Vocabulary Vocabulary skills 4 5 73 0.10 (–0.23 to 0.42)
Rey Complex Figure test (copy) Perceptual organisation 5 9 157 0.09 (–0.14 to 0.31)
Boston Naming Test Verbal naming 4 6 437 –0.02 (–0.17 to 0.11)

The estimated effects for all the tasks analysed are presented in graphical form to facilitate comparison (Fig. 2).

Fig. 2 Change (estimated effects and confidence intervals) in the cognitive variables analysed in participants with schizophrenia. CVLT, California Verbal Learning Test; DSDT, Digit Span Distractibility Test; HVLT, Hopkins Verbal Learning Test; LM, Logical Memory; PE, perseverative errors; RAVLT, Rey Auditory Verbal Learning Test; TMT–A/B, Trail Making Test part A/B; VR, Visual Reproduction; WCST, Wisconsin Card Sorting Test; WMS, Wechsler Memory Scale.

Potential moderator factors

We analysed the impact of six potential moderator factors (time between evaluations; participants' diagnosis; change in treatment; difference in chlorpromazine equivalents; percentage change in negative symptoms; percentage change in positive symptoms) on the test–retest difference for variables for which data from at least ten samples were available – i.e. 17 variables: Visual Reproduction (immediate and delayed recall); Logical Memory (immediate and delayed recall); Verbal Fluency (Letters and Categories); WCST (number of perseverative errors, percentage perseverative errors, number of categories completed); TMT–A and TMT–B (time); RAVLT (immediate recall); HVLT (immediate recall); Digit Symbol Substitution; Block Design; Digit Span; and Similarities. The interval between the two evaluations and the participants' diagnoses were reported in all cases. Data for the other potential moderators were reported less frequently, but it was none the less possible – except for dosage of antipsychotic drugs – to analyse their influence on all 17 variables. We were able to analyse the influence of antipsychotic drug dosage on only 7 variables: Verbal Fluency (Letters), WCST (number of preservative errors, percentage of perseverative errors, number of categories completed); time for TMT–A and B; and Block Design. The results of most of these analyses were not significant. The significant results are summarised below.

For TMT–B (time), patients who changed treatment from neuroleptics to novel antipsychotic drugs showed a significantly larger improvement in performance (estimated effect 0.33, 95% CI 0.19 to 0.47) than patients who remained on the same type of treatment (either neuroleptics or atypical antipsychotic drugs) for both test and retest (estimated effect 0.12, 95% CI −0.01 to 0.25). Similar results were obtained for Visual Reproduction (delayed recall). Patients who changed treatment between the two assessments performed better on retest (estimated effect 0.45, 95% CI 0.18 to 0.72) than those who remained on the same treatment (estimated effect −0.07, 95% CI −0.42 to 0.28). For the Block Design task, patients remaining on the same dosage of antipsychotic medication (in chlorpromazine equivalents) performed better (estimated effect 0.23, 95% CI −0.11 to 0.57) than those whose dosage of antipsychotic medication was decreased (estimated effect −0.06; 95% CI −0.36 to 0.25). The time between the two trials significantly affected performance in the Logical Memory (delayed recall) and Visual Reproduction (delayed recall) tests. As expected, the improvement in performance for these variables was inversely related to the time between test and retest.

Test–retest results for control groups

The studies included in our analysis provided sufficient data for estimation of the differences between test and retest in ‘internal’ controls for only 9 variables. With the addition of supplementary data (samples of controls from other studies: ‘external’ controls), we had sufficient data to estimate the effects for 19 of the 31 variables. Table 5 summarises our findings for the controls. We present data for controls from studies included in our meta-analysis and for these data combined with data from the studies cited by McCaffrey et al Reference McCaffrey, Duff and Westervelt6,Reference McCaffrey, Duff and Westervelt7 – ‘all controls’. Data for the same variables in participants with schizophrenia are provided for comparison.

Table 5 Changes in the cognitive variables in the control samples compared with changes in the schizophrenia samples

Controls from the studies included in our meta-analysis All controls a Patients with schizophrenia
Test Variable Studies n Participants n Estimated effect (95% CI) Studies n Participants n Estimated effect (95% CI) Estimated effect (95% CI)
Logical Memory Immediate 4 93 0.54 * b (–0.31 to 1.38) 9 805 0.26 b (0.01 to 0.52) 0.29 (0.14 to 0.44)
Logical Memory Delayed Not enough data 9 704 0.46 * b (0.20 to 0.72) 0.30 (0.16 to 0.45)
Visual Reproduction Immediate 5 126 –0.28 b (–0.87 to 0.32) 9 717 0.19 b , c (–0.07 to 0.45) 0.15 (0.01 to 0.29)
Visual Reproduction Delayed 5 126 0.37 b , d (–0.43 to 1.16) 7 518 0.37 c (0.25 to 0.49) 0.30 (0.16 to 43)
WCST Categories completed 3 89 0.24 * (–0.06 to 0.54) 5 129 0.19 * (–0.05 to 0.44) 0.08 (–0.03 to 0.18)
WCST Errors Not enough data 3 46 0.31 c , d (–0.10 to 0.72) 0.17 (0.01 to 0.34)
WCST Perseverative errors 4 61 0.43 (0.05 to 0.82) 6 101 0.38 * (0.10 to 0.66) 0.18 (0.04 to 0.31)
TMT–A Time 4 64 0.44 * d (0.13 to 0.76) 12 361 0.34 c (0.19 to 0.48) 0.26 (0.15 to 0.36)
TMT–B Time 5 126 0.15 (–0.12 to 0.42) 15 541 0.30 * (0.18 to 0.42) 0.18 (0.10 to 0.27)
Verbal Fluency Letters 3 75 0.28 * (–0.04 to 0.61) 11 582 0.28 * c (0.17 to 0.40) 0.18 (0.09 to 0.26)
Verbal Fluency Categories Not enough data 5 1198 –0.10 c , d (–0.18 to 0.19) 0.02 (–0.10 to 0.14)
Boston Naming Test Immediate Not enough data 5 245 0.06 (–0.11 to 0.24) –0.02 (–0.17 to 0.11)
Stroop words Not enough data 4 98 0.17 (–0.11 to 0.45) 0.13 (–0.10 to 0.35)
Stroop coloured dots Not enough data 3 80 –0.06 (–0.37 to 0.25) 0.15 (–0.08 to 0.37)
Stroop coloured words Not enough data 6 134 –0.03 (–0.27 to 0.21) 0.28 * b (0.02 to 0.53)
Similarities Not enough data 5 513 0.15 (0.03 to 0.27) 0.31 (0.10 to 0.52)
Block Design Not enough data 10 680 0.16 c (0.06 to 0.27) 0.22 (0.10 to 0.35)
Digit Span Not enough data 10 472 0.09 (–0.04 to 0.22) 0.13 (–0.03 to 0.28)
Digit Symbol Substitution 5 136 0.38 (0.13 to 0.63) 18 1115 0.21 c (0.13 to 0.30) 0.29 (0.20 to 0.39)

a. Controls from the studies included in the meta-analysis combined with samples from other studies

b. Calculated using a random effect model

c. Significantly older than schizophrenia groups included in our meta-analysis

d. Interval between the two evaluations significantly longer than in the schizophrenia groups included in our meta-analysis

* P<0.05 for difference compared with participants with schizophrenia

The data suggested a definite practice effect (improvement statistically different from 0) in 10 of the 19 variables, a possible practice effect (improvement between test and retest, but with a confidence interval including 0) in 6 variables and no improvement in the remaining 3 variables (with no variable significantly deteriorating). Comparisons of those data with data from the schizophrenia group may be summarised as follows. For variables showing a significant practice effect, no significant difference was observed for 6 variables and controls improved significantly more than the participants with schizophrenia for the other 4 variables. For the variables with a possible practice effect, improvement was significantly greater for controls on one measure, with no significant difference for the other five. Participants with schizophrenia showed no significant difference from controls for 2 of the 3 variables for which no improvement was observed in controls, but a significant improvement was observed in the number of words in the interference task of the Stroop test. Comparisons of data from ‘internal controls’ and participants with schizophrenia gave similar results, with no significant difference in improvement for 4 variables and significantly higher levels of improvement in controls for the other 5 variables.

We evaluated the differences between studies assessing controls or participants with schizophrenia by comparing the testing (interval between test and retest) and demographic (age of the participants) characteristics available for all samples. The significant differences are indicated in Table 5. Similar improvements in performance were observed in controls and in participants with schizophrenia whose medication type changed, for the TMT–B (0.30, 95% CI 0.18 to 0.42) and for Visual Reproduction (delayed recall) (0.37, 95% CI 0.25 to 0.49), whereas for the same variables, controls showed a significantly larger improvement in performance than patients remaining on the same medication.


Several reviews Reference Rund4,Reference Spohn and Strauss18 and meta-analyses Reference Keefe, Silva, Perkins and Liebermann19Reference Woodward, Purdon, Meltzer and Zald21 have already been published on the topic of cognitive change in schizophrenia. Overall, these analyses suggest that there is no progressive impairment for most cognitive variables and that, for some cognitive domains, improvement is possible after the onset of the disorder. These previous studies were, in our view, subject to several limitations. First, with the exception of Rund's review, they aimed to examine the effects of medication on cognitive functions in schizophrenia. This resulted in the exclusion of several primary studies and over-representation of studies with short test–retest intervals. Another limitation is that the results of these studies were presented as composite scores for broad cognitive functions (e.g. executive functions, memory). This is a convenient way to summarise findings, but it combines data from tests exploring different cognitive processes (e.g. memory tests assessing immediate or delayed recall, learning or recognition), generating results of questionable theoretical relevance. Furthermore, the results obtained do not help researchers to select the most useful tests or variables based on stability or sensitivity to change. Another important methodological problem is that changes in the samples of people with schizophrenia were not compared with changes in control groups. Thus, when improvement is observed it is unclear how much is due to learning or practice effects and how much is due to a genuine improvement in cognitive abilities. We tried to overcome these limitations by including in our meta-analysis all the available studies in which the same group of people with schizophrenia underwent cognitive testing on two occasions more than 1 month apart. We analysed each variable separately and, when possible, we also calculated changes over time in the cognitive performances of normal controls.

Given the methodological differences cited above, it is interesting to compare our results with those of previous studies, especially that of Woodward et al, Reference Woodward, Purdon, Meltzer and Zald21 which is the most recent of these studies and used similar statistical methods. Our estimated effect sizes were smaller than those in Woodward's study and the estimated effects showed a broader distribution (from −0.02 to 0.53 v. 0.17 to 0.46 in Woodward's study). Our estimated effect sizes might be lower because we tried to limit the effect of practice by including only studies in which the test–retest interval was greater than 1 month (Woodward et al also included studies with a test–retest interval of between 1 week and 1 month), and by using only the results of the first and second evaluations from studies reporting several successive evaluations (whereas Woodward et al used the first and last evaluations). The broader distribution of the estimated effects probably results from the effects being reported separately for each variable. However, there are also some similarities in the results reported by these two meta-analyses. In both Woodward's review and our own analysis, the greatest differences in effect sizes were observed in the memory tests (Learning and Delayed Recall domains, 0.46 and 0.43 respectively), with tests of ‘cognitive flexibility and abstraction’ (0.38) and ‘vigilance and attention’ (0.35) showing milder improvement.

Influence of moderator factors

When enough data were available we assessed the effect of potential moderator factors on cognitive changes between test and retest. Participants with schizophrenia showed significantly greater improvements in performance if the total antipsychotic dosage was maintained (for Block Design), if the test–retest interval was shorter (delayed recall for Logical Memory and Visual Reproduction) and if treatment was changed from conventional to novel antipsychotic drugs (TMT–B time and Visual Reproduction delayed recall tests).

The two tests showing a greater improvement with shorter test–retest intervals were both memory tests. Memory measures are among the most susceptible to the effects of practice and the test–retest interval has a substantial influence on the magnitude of the practice effect. Reference McCaffrey, Duff and Westervelt7 Thus, the pattern of results for these two tests may be accounted for by the effect of practice. For two other variables, TMT–B time and Visual Reproduction delayed recall, a significantly greater improvement was observed if the patient's medication had been switched from a conventional to a novel antipsychotic drug. These results may suggest that atypical antipsychotic drugs have more beneficial effects on cognition than typical neuroleptics. However, this difference was relatively small and limited to a few cognitive variables (significant improvements in only 2 of the 17 cognitive variables tested).

Furthermore, there are at least two potential sources of bias that might lead to these conclusions: publication bias (particularly for studies sponsored by pharmaceutical companies), and the fact that changes between the two antipsychotic drug categories were always in the same direction (conventional to novel antipsychotic drugs). Patients are generally included in such studies because of the inefficacy of their current treatment and/or the presence of adverse effects. Thus, the cognitive improvement might result from the withdrawal of an ineffective treatment or the removal of an adverse effect, rather than from a specific positive action of a new antipsychotic drug. If treatment change is itself the factor associated with improvement, then changes in medication for the same reasons (inefficacy and/or adverse effects) in the other direction (i.e. from atypical to typical antipsychotic drugs) should also result in cognitive improvement. To our knowledge, this hypothesis has not been tested. In addition, some of the observed differences may not be due to the specific action of the two classes of antipsychotic drug, and may instead be due to atypical antipsychotic drugs having fewer extrapyramidal adverse effects and, in some cases, normothymic effects. Thus, patients taking such medication require fewer prescriptions of anticholinergic and/or normothymic drugs, both of which are known to have mildly deleterious effects on cognition.

Overall, our results concerning the role of potential moderators must be regarded as exploratory and interpreted with caution for two reasons. First, not all the studies provided data, limiting our ability to assess the influence of some of these moderators. Second, the large number of statistical tests might have led to spurious findings due to type I errors.

Comparison with performances in controls: role of the practice effect

The observed improvements in the performances of participants with schizophrenia may result from real improvements in cognition, a practice (learning) effect or a combination of the two. In samples of adult controls, improvements in cognitive performance assessed on two separate occasions are mostly due to practice effects. In older control group participants, this effect may be combined with a slight deterioration of performance (especially in memory and timed tests).

We were able to estimate the test–retest effect in controls for only 19 of the 31 variables. Test variables showing a possible or definite practice effect among patients with schizophrenia fell into two categories: variables for which the schizophrenia and control groups showed similar improvement, and variables for which the improvement was smaller than expected in the schizophrenic group. In other words, for these tests, the improvement in the schizophrenia group never exceeded the practice effect. As the control groups were older than the schizophrenia groups for most of the variables (and the test–retest interval was also longer for two of the variables), differences between control and schizophrenia groups might have been underestimated. For only one variable (number of words in the interference task of the Stroop test), which showed no practice effect, improvement was greater in the schizophrenia group than in controls. However, this result should be interpreted with caution because the total control group was small and the data for the schizophrenia group were heterogeneous. These data suggest that, for most variables, the practice effect alone might account for the improvement observed in people with schizophrenia and might mask an actual deterioration in some cognitive processes.

Given the size and extensive impact of the practice effect, this effect should be taken into account in the design of future studies. The use of a control group is therefore of paramount importance, to ensure that results can correctly be interpreted as indicating improvement or deterioration in the cognitive abilities of people with schizophrenia. For example, in our meta-analysis, patients with schizophrenia showed similar improvements for delayed recall in the Logical Memory task and in the number of words in the interference condition of the Stroop test; however, when these results were compared with those for controls, conflicting interpretations were obtained (deterioration in the memory task but improvement in the Stroop test). It may also be important to match the two groups – schizophrenia and controls – not only in terms of demographic characteristics (age, gender, etc.), but also for familiarity with the tests used and, more generally, familiarity with testing situations. This is likely to be true for longitudinal studies, but is probably even more important for studies comparing the performances of different populations with a single evaluation.

Semantic verbal fluency as a potential endophenotype

Our results suggest that semantic Verbal Fluency (Categories), for which stable results were obtained in patients (estimated effect 0.02) and a slight (statistically non-significant) decrease over time was observed in controls (estimated effect −0.10), may represent the most promising potential endophenotype. The slight decrease observed in controls might have resulted from the inclusion of a large number of older people in the group (mean age 73.4 years). There are also other arguments to support the use of semantic verbal fluency as a potential endophenotype. The Categories Verbal Fluency test is one of the measures showing the highest degree of impairment in patients with schizophrenia Reference Heinrichs and Zakzanis22 and in first-degree relatives of such patients. Reference Szoke, Schürhoff, Mathieu, Meary, lonescu and Leboyer23,Reference Snitz, Macdonald and Carter24

Lexical verbal fluency, which is similar to semantic verbal fluency in the test format and, to some extent, in the cognitive processes involved (e.g. general retrieval), does not share these qualities. Lexical verbal fluency is less impaired than semantic verbal fluency in people with schizophrenia Reference Bokat and Goldberg25,Reference Henry and Crawford26 and in their relatives. Reference Szoke, Schürhoff, Mathieu, Meary, lonescu and Leboyer23,Reference Snitz, Macdonald and Carter24 Furthermore, in our analysis Verbal Fluency (Letters) scores improved significantly in both participants with schizophrenia and controls.

Keefe et al Reference Keefe, Silva, Perkins and Liebermann19 and Woodward et al Reference Woodward, Purdon, Meltzer and Zald21 identified verbal fluency as one of the cognitive domains showing significant improvement in patients treated with novel antipsychotic drugs. Heinrichs & Zakzanis Reference Heinrichs and Zakzanis22 found a strong trend for patients taking high dosages of medication (chlorpromazine equivalents) to show lower levels of verbal fluency impairment. However, all these studies used a composite score based on data from both the Letters and Categories Verbal Fluency measures, and they therefore do not contradict our conclusion that semantic verbal fluency is stable.

The only other test showing similar, stable results in control and schizophrenia groups was the Boston Naming Test, which is also sensitive to the integrity of the semantic store.


The results of our analysis must be interpreted bearing its limitations in mind. Most of these limitations result from the small number of primary studies available, and from heterogeneity in the tests used and in data collection and reporting. More than half the potentially relevant studies were excluded for various reasons. Some studies were excluded because of major methodological differences (e.g. inclusion of patients with diagnoses other than psychotic disorders), but 39 studies were excluded simply because data for individual tests were not provided. This clearly represents a major loss of information, although it is not clear what effect this information would have had on our results. Differences in the variables reported limited our ability to detect a significant effect of moderators. Finally, the lack of a healthy control group in most studies limited the interpretation of the results. We tried to palliate this problem by including controls from other studies, but this resulted in large differences in demographic (e.g. age) and study (e.g. time between test and retest) characteristics. Furthermore, we did not carry out a systematic review of the data for controls and we included no recent data (subsequent to the publication of two books by McCaffrey et al). Reference McCaffrey, Duff and Westervelt6,Reference McCaffrey, Duff and Westervelt7


This research was supported by grants from Institut National de la Santé et de la Recherche Médicale (INSERM) and the Délégation à la Recherche Clinique de l'Assistance Publique – Hôpitaux de Paris (PHRC AOM 98152).


Declaration of interest



1 Goldberg, TE, Weinberger, DR, Berman, KF, Pliskin, NH, Podd, MH. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 1987; 44: 1008–14.CrossRefGoogle ScholarPubMed
2 Bilder, RM, Lipschutz-Broch, L, Reiter, G, Geisler, S, Mayerhoff, D, Lieberman, JA. Neuropsychological deficits in the early course of first episode schizophrenia. Schiz Res 1991; 5: 198–9.CrossRefGoogle ScholarPubMed
3 DeLisi, LE, Tew, W, Xie, S, Hoff, AL, Sakuma, M, Kushner, M, Lee, G, Shedlack, K, Smith, AM, Grimson, R. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry 1995; 38: 349–60.CrossRefGoogle ScholarPubMed
4 Rund, BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schiz Bull 1998; 24: 425–35.CrossRefGoogle ScholarPubMed
5 Gold, JM. Cognitive deficits as treatment targets in schizophrenia. Schiz Res 2004; 72: 21–8.CrossRefGoogle Scholar
6 McCaffrey, RJ, Duff, K, Westervelt, HJ (eds). Practitioner's Guide to Evaluating Change with Intellectual Assessment Instruments. Springer, 2000.CrossRefGoogle Scholar
7 McCaffrey, RJ, Duff, K, Westervelt, HJ (eds). Practitioner's Guide to Evaluating Change with Neuropsychological Assessment Instruments. Springer, 2000.Google Scholar
8 Hedges, LV, Olkin, I. Statistical Methods for Meta-analysis. Academic Press, 1985.Google Scholar
9 Higgins, J, Thompson, S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.CrossRefGoogle ScholarPubMed
10 Arthur, W, Bennett, W, Huffcutt, A. Conducting Meta-Analysis Using SAS. Erlbaum, 2001.Google Scholar
11 DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.CrossRefGoogle ScholarPubMed
12 Wang, MC, Bushman, BJ. Integrating Results Through Meta-analytic Review Using SAS Software. SAS Institute, 1999.Google Scholar
13 Stip, E, Remington, GJ, Dursun, SM, Reiss, JP, Rotstein, E, MacEwan, GW, Chokka, PR, Jones, B, Dickson, RA; on behalf of the Canadian Switch Study Group. A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. J Clin Psychopharmacol 2003; 23: 400–4.CrossRefGoogle ScholarPubMed
14 Purdon, SE, Jones, BDW, Stip, E, Labelle, A, Addington, D, David, SR, Breier, A, Tollefson, GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Arch Gen Psychiatry 2000; 57: 249–58.CrossRefGoogle ScholarPubMed
15 Purdon, SE, Malla, A, Labelle, A, Lit, W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosc 2001; 26: 137–49.Google ScholarPubMed
16 Penades, R, Boget, T, Catalan, R, Bernardo, M, Gasto, C, Salamero, M. Cognitive mechanisms, psychosocial functioning and neurocognitive rehabilitation in schizophrenia. Schizophr Res 2003; 63: 219–27.CrossRefGoogle Scholar
17 Green, MF, Marshall, BD, Wirshing, WC, Ames, D, Marder, SR, McGurk, S, Kern, RS, Mintz, J. Does risperidone improves verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799804.Google Scholar
18 Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989; 98: 367–80.CrossRefGoogle Scholar
19 Keefe, RS, Silva, SG, Perkins, DO, Liebermann, JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201–22.CrossRefGoogle ScholarPubMed
20 Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176–84.CrossRefGoogle ScholarPubMed
21 Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457–72.CrossRefGoogle Scholar
22 Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426–45.CrossRefGoogle Scholar
23 Szoke, A, Schürhoff, F, Mathieu, F, Meary, A, lonescu, S, Leboyer, M. Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychol Med 2005; 35: 771–82.CrossRefGoogle ScholarPubMed
24 Snitz, BE, Macdonald, AW, Carter, CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006; 32: 179–94.Google ScholarPubMed
25 Bokat, CE, Goldberg, TE. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res 2003; 64: 73–8.CrossRefGoogle ScholarPubMed
26 Henry, JD, Crawford, JR. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. Cognit Neuropsychiatry 2005; 10: 133.CrossRefGoogle ScholarPubMed
27 Albus, M, Hubmann, W, Scherer, J, Dreikorn, B, Hecht, S, Sobizack, N, Mohr, F. A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 2002; 252: 262–7.CrossRefGoogle ScholarPubMed
28 Bilder, RM, Goldman, RS, Volavka, J, Czobor, P, Hoptman, M, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, J, Kunz, M, Chakos, M, Cooper, TB, Horowitz, TL, Lieberman, JA. Neurocognitive effect of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–28.CrossRefGoogle ScholarPubMed
29 Bryson, G, Tamasine, G. Longitudinal Wisconsin card sorting performance in schizophrenia patients in rehabilitation. Appl Neuropsychol 2002; 4: 203–9.Google Scholar
30 Buchanan, RW, Holstein, C, Breier, A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36: 717–25.CrossRefGoogle ScholarPubMed
31 Chua, L, Chong, SA, Pang, SA, Ng, VP, Chan, YH. The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. Singapore Med J 2001; 42: 243–6.Google Scholar
32 Cuesta, MJ, Peralta, V, Zarzuela, A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001; 48: 1728.CrossRefGoogle ScholarPubMed
33 de Beaurepaire, C, de Beaurepaire, R, Cleau, M, Borenstein, P. Bromocriptine improves digit symbol substitution test scores in neuroleptic-treated chronic schizophrenic patients. Eur Psychiatry 1993; 8: 8993.Google Scholar
34 Deutsch, SI, Schwartz, BL, Rosse, RB, Mastropaolo, J, Marvel, CL, Drapalski, AL. Adjuvant topiramate administration: a pharmacological strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003; 26: 199206.CrossRefGoogle Scholar
35 Fields, RB, Van Kammen, DP, Peters, JL, Rosen, J, Van Kammen, WB, Nugent, A, Stipetic, M, Linnoila, M. Clonidine improves memory function in schizophrenia independently from change in psychosis. Schizophr Res 1988; 1: 417–23.CrossRefGoogle ScholarPubMed
36 Fujii, DE, Ahmed, I, Jokumsen, M, Compton, JA. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 1997; 9: 240–5.Google ScholarPubMed
37 Gold, S, Arndt, S, Nopoulos, P, O'Leary, DS, Andreasen, N. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999; 156: 1342–8.Google ScholarPubMed
38 Goldberg, TE, Greenberg, RD, Griffin, SJ, Gold, JM, Kleinman, JE, Pickar, D, Schulz, SC, Weinberger, DR. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162: 43–8.CrossRefGoogle ScholarPubMed
39 Grawe, RW, Levander, S. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Acta Psychiatr Scand 2001; 104: 60–4.CrossRefGoogle Scholar
40 Green, MF, Marder, SR, Glynn, SM, McGurk, SR, Wirshing, WC, Wirshing, DA, Liberman, RP, Mintz, J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002; 51: 972–8.CrossRefGoogle ScholarPubMed
41 Hagger, C, Buckley, P, Kenny, J, Friedman, L, Ubogy, D, Meltzer, HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702–12.CrossRefGoogle ScholarPubMed
42 Harris, MJ, Heaton, RK, Schalz, A, Bailey, A, Patterson, TL. Neuroleptic dose reduction in older psychotic patients. Schizophr Res 1997; 27: 241–8.CrossRefGoogle ScholarPubMed
43 Harvey, PD, Lombardi, J, Liebman, M, White, L, Parella, M, Powchik, P, Davidson, M. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res 1996; 22: 223–31.CrossRefGoogle ScholarPubMed
44 Harvey, PD, Meltzer, H, Simpson, GM, Potkin, SG, Loebel, A, Siu, C, Romano, SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004; 66: 101–13.CrossRefGoogle ScholarPubMed
45 Harvey, PD, Palmer, BW, Heaton, RK, Mohamed, S, Kennedy, J, Brickman, A. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 2005; 162: 110–17.CrossRefGoogle ScholarPubMed
46 Hill, SK, Schuepbach, D, Herbener, ES, Keshavan, MS, Sweeney, JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. Schizophr Res 2004; 68: 4963.CrossRefGoogle ScholarPubMed
47 Hoff, AL, Faustman, WO, Wieneke, M, Espinoza, S, Costa, M, Wolkowitz, O, Csernansky, JG. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996; 15: 361–9.CrossRefGoogle ScholarPubMed
48 Hoff, AL, Svetina, C, Shields, G, Stewart, J, DeLisi, LE. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res 2005; 78: 2734.CrossRefGoogle ScholarPubMed
49 Hughes, C, Kumari, V, Soni, W, Das, M, Binneman, B, Drozd, S, O'Neil, S, Mathew, V, Sharma, T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 2002; 59: 137–46.Google Scholar
50 Killian, G, Holzman, PS, Davis, JM, Gibbons, R. Effects of psychotic medication on selected cognitive and perceptual measures. J Abnorm Psychol 1984; 1: 5870.CrossRefGoogle Scholar
51 Ljubin, T, Zakic-Milas, D, Mimica, N, Folnegović-Smalc, V, Makarić, G. A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol 2000; 15: 513–19.3.0.CO;2-Y>CrossRefGoogle ScholarPubMed
52 Lysaker, P, Bell, M. Performance on repeated administrations of the Wisconsin Card Sorting Test. J Nerv Ment Dis 1994; 182: 656–60.CrossRefGoogle ScholarPubMed
53 Manschreck, TC, Redmond, DA, Candela, SF, Maher, BA. Effects of clozapine on psychiatric symptoms, cognition and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci 1999; 11: 481–9.CrossRefGoogle Scholar
54 McGrath, J, Scheldt, S, Welham, J, Clair, A. Performance on tests sensitive to impaired executive ability in schizophrenia and well controls: acute and subacute phases. Schizophr Res 1997; 26: 127–37.CrossRefGoogle ScholarPubMed
55 McGurk, SR, Moriarty, PJ, Harvey, PD, Parrella, M, White, L, Davis, KL. The longitudinal relationship of clinical symptoms, cognitive functioning and adaptative life in geriatric schizophrenia. Schizophr Res 2000; 42: 4755.CrossRefGoogle Scholar
56 McGurk, SR, Mueser, KT, Harvey, PD, LaPuglia, R, Marder, J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv 2003; 54: 1129–35.CrossRefGoogle ScholarPubMed
57 Nopoulos, P, Flashman, L, Flaum, M, Arndt, S, Andreasen, N. Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res 1994; 14: 2937.CrossRefGoogle ScholarPubMed
58 Prescott, CA, Strauss, ME, Tune, LE. Test-retest reliability of information-processing measures among chronic schizophrenics. Psychiatry Res 1986; 17: 199202.CrossRefGoogle ScholarPubMed
59 Purdon, SE, Labelle, A, Boulay, L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 2001; 48: 5767.CrossRefGoogle ScholarPubMed
60 Rosmark, B, Ösby, U, Engelbrektson, K, Nyman, H. Stability of performance on neuropsychological tests in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249: 299304.CrossRefGoogle ScholarPubMed
61 Rossi, A, Mancini, F, Stratta, P, Mattei, P, Gismondi, R, Pozzi, F, Casacchia, M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997; 95: 40–3.CrossRefGoogle Scholar
62 Rund, BR. Distractibility and recall capability in schizophrenics, a 4 year longitudinal study of stability in cognitive performance. Schizophr Res 1989; 2: 265275.CrossRefGoogle ScholarPubMed
63 Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study v. One-year follow-up. Br J Psychiatry 1988; 152: 470476.CrossRefGoogle Scholar
64 Seidman, LJ, Pepple, JR, Faraone, SV, Kremen, WS, Cassens, G, McCarley, RW, Tsuang, MT. Wisconsin Card Sorting Test performance over time in schizophrenia, preliminary evidence from clinical follow-up and neuroleptic reduction studies. Schizophr Res 1991; 5: 233242.CrossRefGoogle ScholarPubMed
65 Seidman, LJ, Pepple, JR, Faraone, SV, Kremen, WS, Green, AI, Brown, WA, Tsuang, MT. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biol Psychiatry 1993; 33: 575584.CrossRefGoogle ScholarPubMed
66 Sharma, T, Hughes, C, Soni, W, Kumari, V. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology 2003; 169: 398403.CrossRefGoogle ScholarPubMed
67 Smith, TE, Hull, JW, Huppert, JD, Silverstein, SM. Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. Schizophr Res 2002; 55: 229237.CrossRefGoogle ScholarPubMed
68 Stirling, J, White, C, Lewis, S, Hopkins, R, Tantam, D, Huddy, A, Montague, L. Neurocognitive function and outcome in first-episode schizophrenia: A 10-year follow-up of an epidemiological cohort. Schizophr Res 2003; 65: 7586.CrossRefGoogle ScholarPubMed
69 Sweeney, JA, Hass, GL, Kelip, JG, Long, M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year follow-up study. Psychiatry Res 1991; 38: 6376.CrossRefGoogle Scholar
70 Townsend, L, Norman, RMG, Malla, AK, Rychlo, AD, Ahmed, RR. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorder. Psychiatry Res 2002; 113: 6981.CrossRefGoogle Scholar
71 Van der Gaag, M, Kern, RS, van den Bosch, RJ, Liberman, RP. A controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2002; 28: 167176.CrossRefGoogle Scholar
72 Velligan, DI, Newcomer, J, Pultz, J, Csernansky, J, Hoff, AL, Mahurin, R, Miller, AL. Does cognitive function improve with quetiapine in comparison to haloperidol. Schizophr Res 2002; 53: 239248.CrossRefGoogle ScholarPubMed
73 Verdoux, H, Magnin, E, Bourgeois, M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr Res 1995; 14: 133139.CrossRefGoogle Scholar
74 Wölwer, W, Gaebel, W. Impaired Trail-Making Test–B performance in patients with acute schizophrenia is related to inefficient sequencing of planning and acting. J Psychiatr Res 2002; 36: 407416.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1 Selection process for the articles included in the meta-analysis.

Figure 1

Table 1 Change between test and retest in variables derived from the memory tests

Figure 2

Table 2 Change between test and retest in variables derived from the executive tests

Figure 3

Table 3 Change between test and retest in variables derived from the attention tests

Figure 4

Table 4 Change between test and retest in variables derived from the ‘other’ (not classified) tests

Figure 5

Fig. 2 Change (estimated effects and confidence intervals) in the cognitive variables analysed in participants with schizophrenia. CVLT, California Verbal Learning Test; DSDT, Digit Span Distractibility Test; HVLT, Hopkins Verbal Learning Test; LM, Logical Memory; PE, perseverative errors; RAVLT, Rey Auditory Verbal Learning Test; TMT–A/B, Trail Making Test part A/B; VR, Visual Reproduction; WCST, Wisconsin Card Sorting Test; WMS, Wechsler Memory Scale.

Figure 6

Table 5 Changes in the cognitive variables in the control samples compared with changes in the schizophrenia samples

Supplementary material: PDF

Szöke et al. supplementary material

Supplementary Material

Download Szöke et al. supplementary material(PDF)
Supplementary material: File

Szöke et al. supplementary material

Supplementary Material

Download Szöke et al. supplementary material(File)
File 508 Bytes
Submit a response


No eLetters have been published for this article.
You have Access
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Longitudinal studies of cognition in schizophrenia: Meta-analysis